论文部分内容阅读
南宁市制药厂最近完成了靶向抗癌新药复方氟尿嘧啶多相脂质体(代号139—3号)的试制与放大生产,于11月28日在广西医药管理局和南宁市经委主持下通过鉴定。广西卫生厅已批准生产。复方氟尿嘧啶多相脂质体被称为“导弹式”超微粒药物载体的抗癌新剂型,是沈阳药学院顾学裘教授领导下,沈阳与上海两个单位合作创制的科研成果,目前在技术上处于国内外领先地位。其特点是剂型设计上应用了祖国医学的“扶正祛邪、攻补兼施”的法则。
Nanning Pharmaceutical Factory recently completed the trial production and enlargement production of the new anticancer drug compound fluorouracil multiphase liposome (code 139-3), passed the appraisal under the auspices of Guangxi Medical Administration and Nanning Economic Commission on November 28 . Guangxi Health Department has approved the production. Compound fluorouracil multiphasic liposomes known as “missile” ultra-particulate drug carrier anticancer new formulations, is under the leadership of Professor Gu Xueqiu Shenyang Pharmaceutical College, Shenyang and Shanghai jointly developed two units of scientific research, currently technically in Leading position at home and abroad. It is characterized by the application of the formula design of the motherland medicine, “Fuzhengqixie, Gongzhuhuishi” rule.